Bafiertam vs Dimethyl fumarate (Tecfidera)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Sclerosis

Shared mechanism: Nrf2 pathway (fumaric acid ester) · full Multiple Sclerosis pipeline

Bafiertam

Marketed by Cycle Pharmaceuticals Ltd.

Approved in Multiple Sclerosissmall molecule (fumarate)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Dimethyl fumarate (Tecfidera)

Marketed by Biogen

Approved in Multiple Sclerosissmall molecule
Reliable signal

NCT00451451 · Phase 3 · completed

This was a large (n=1417), randomized, double-blind, placebo-controlled Phase 3 trial with a hard clinical primary endpoint (annualized relapse rate, independently adjudicated). Both BG00012 dosing arms showed clearly separated confidence intervals from placebo on this primary endpoint (0.224 and 0.198 relapses/year vs 0.401 for placebo), indicating the drug met its primary comparison in the favorable direction, satisfying all the elements of well-designed, positive Phase 3 evidence.

Reported efficacy

Annualized Relapse Rate (2 years): Adjusted annualized relapse rate at 2 years: 0.224 relapses/year (95% CI 0.179–0.282) with BG00012 240 mg BID vs 0.401 (95% CI 0.329–0.488) with placebo; 0.198 (95% CI 0.156–0.252) with BG00012 240 mg TID vs 0.401 (95% CI 0.329–0.488) with placebo. (met)

Result source: NCT00451451

Results for Multiple Sclerosis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBafiertamDimethyl fumarate (Tecfidera)
Annualised relapse rate—Not reported0.2 vs 0.4−0.2 vs placebo240 mg twice daily · wk 104 · n 359NCT00451451
5 other results
  • 0.2 vs 0.4 240 mg 3 times daily · wk 104 · n 345 · Phase 3 · primary NCT00451451
  • 0.2 vs 0.4 240 mg BID · wk 104 · n 410 · Phase 3 · secondary NCT00420212
  • 0.2 vs 0.4 240 mg TID · wk 104 · n 416 · Phase 3 · secondary NCT00420212
  • 0.2 vs 0.5 wk 96 · n 78 · Phase 3 · secondary NCT02283853
  • 0.3 vs 0.6 wk 48 · n 78 · Phase 3 · secondary NCT02283853
Free of 3-month confirmed disability progression (%)—Not reported—Not reported
New or enlarging T2 lesions—Not reported—Not reported

Annualised relapse rate

Bafiertam
—Not reported
Dimethyl fumarate (Tecfidera)
0.2 vs 0.4−0.2 vs placebo240 mg twice daily · wk 104 · n 359NCT00451451
5 other results
  • 0.2 vs 0.4 240 mg 3 times daily · wk 104 · n 345 · Phase 3 · primary NCT00451451
  • 0.2 vs 0.4 240 mg BID · wk 104 · n 410 · Phase 3 · secondary NCT00420212
  • 0.2 vs 0.4 240 mg TID · wk 104 · n 416 · Phase 3 · secondary NCT00420212
  • 0.2 vs 0.5 wk 96 · n 78 · Phase 3 · secondary NCT02283853
  • 0.3 vs 0.6 wk 48 · n 78 · Phase 3 · secondary NCT02283853

Free of 3-month confirmed disability progression (%)

Bafiertam
—Not reported
Dimethyl fumarate (Tecfidera)
—Not reported

New or enlarging T2 lesions

Bafiertam
—Not reported
Dimethyl fumarate (Tecfidera)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Bafiertam: 2 of 4 rows · Dimethyl fumarate (Tecfidera): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBafiertamDimethyl fumarate (Tecfidera)
Dropout rate
—a
NCT04570670 · Phase 1
20.9%240 mg 3 times dailyb
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 13 more results
20.9%240 mg twice daily
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
23.1%240 mg TID
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
23.2%240 mg BID
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
55.8%240 mg twice daily
NCT00835770 · Phase 3 · monotherapy
56.8%240 mg three times daily
NCT00835770 · Phase 3 · monotherapy
14.8%
NCT01873417 · Phase 4 · registry result, not featured evidence · monotherapy
21.5%Part 1: BG00012
NCT02283853 · Phase 3 · registry result, not featured evidence
—Part 2: BG00012/ BG00012
NCT02283853 · Phase 3 · registry result, not featured evidence
—
NCT02555215 · Phase 3 · registry result, not featured evidence
27.5%
NCT02525874 · Phase 3 · registry result, not featured evidence
9.1%
NCT02410200 · Phase 2 · registry result, not featured evidence
—Add-on Therapy Period: GA and BG00
NCT01156311 · Phase 2 · registry result, not featured evidence · combination
—Add-on Therapy Period: IFNß and BG
NCT01156311 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
—a
NCT04570670 · Phase 1
7.5%240 mg 3 times dailyb
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 13 more results
5.8%240 mg twice daily
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
8.7%240 mg TID
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
9.8%240 mg BID
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
13%240 mg twice daily
NCT00835770 · Phase 3 · monotherapy
14.3%240 mg three times daily
NCT00835770 · Phase 3 · monotherapy
10.1%
NCT01873417 · Phase 4 · registry result, not featured evidence · monotherapy
6.3%Part 1: BG00012
NCT02283853 · Phase 3 · registry result, not featured evidence
—Part 2: BG00012/ BG00012
NCT02283853 · Phase 3 · registry result, not featured evidence
—
NCT02555215 · Phase 3 · registry result, not featured evidence
7.8%
NCT02525874 · Phase 3 · registry result, not featured evidence
9.1%
NCT02410200 · Phase 2 · registry result, not featured evidence
—Add-on Therapy Period: GA and BG00
NCT01156311 · Phase 2 · registry result, not featured evidence · combination
—Add-on Therapy Period: IFNß and BG
NCT01156311 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
0%a
NCT04570670 · Phase 1
15.7%240 mg 3 times dailyb
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 13 more results
17%240 mg twice daily
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
15.6%240 mg TID
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
18%240 mg BID
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
32.1%240 mg twice daily
NCT00835770 · Phase 3 · monotherapy
31.3%240 mg three times daily
NCT00835770 · Phase 3 · monotherapy
3%
NCT01873417 · Phase 4 · registry result, not featured evidence · monotherapy
23.1%Part 1: BG00012
NCT02283853 · Phase 3 · registry result, not featured evidence
14%Part 2: BG00012/ BG00012
NCT02283853 · Phase 3 · registry result, not featured evidence
10%
NCT02555215 · Phase 3 · registry result, not featured evidence
11.9%
NCT02525874 · Phase 3 · registry result, not featured evidence
22.7%
NCT02410200 · Phase 2 · registry result, not featured evidence
2.1%Add-on Therapy Period: GA and BG00
NCT01156311 · Phase 2 · registry result, not featured evidence · combination
3.5%Add-on Therapy Period: IFNß and BG
NCT01156311 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
a
flushing 60%
abdominal pain 2%
anxiety 2%
NCT04570670 · Phase 1
240 mg 3 times dailyb
flushing 24.1% (placebo 3.6%)
multiple sclerosis relapse 23.5% (placebo 40.5%)
nasopharyngitis 18.3% (placebo 16%)
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 12 more results
240 mg twice daily
flushing 30.6% (placebo 3.6%)
multiple sclerosis relapse 29% (placebo 40.5%)
nasopharyngitis 17.3% (placebo 16%)
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
240 mg TID
flushing 31.7% (placebo 4.9%)
nasopharyngitis 26.2% (placebo 24.8%)
multiple sclerosis relapse 25.7% (placebo 44.4%)
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
240 mg BID
flushing 37.3% (placebo 4.9%)
multiple sclerosis relapse 26.6% (placebo 44.4%)
nasopharyngitis 26.3% (placebo 24.8%)
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
240 mg twice daily
multiple sclerosis relapse 37.3%
nasopharyngitis 25.3%
urinary tract infection 22.6%
NCT00835770 · Phase 3 · monotherapy
240 mg three times daily
multiple sclerosis relapse 38.6%
nasopharyngitis 26%
flushing 19%
NCT00835770 · Phase 3 · monotherapy
abdominal pain 41%
flushing 38.5%
multiple sclerosis relapse 29.5%
NCT02283853 · Phase 3 · registry result, not featured evidence
multiple sclerosis relapse 26.3%
headache 22.8%
covid-19 19.3%
NCT02283853 · Phase 3 · registry result, not featured evidence
flushing 25%
multiple sclerosis relapse 20%
abdominal pain 15%
NCT02555215 · Phase 3 · registry result, not featured evidence
flushing 45.9%
multiple sclerosis relapse 18.8%
nasopharyngitis 15.1%
NCT02525874 · Phase 3 · registry result, not featured evidence
flushing 45.5%
multiple sclerosis relapse 31.8%
abdominal pain 27.3%
NCT02410200 · Phase 2 · registry result, not featured evidence
flushing 53.2%
alanine aminotransferase increased 14.9%
diarrhoea 14.9%
NCT01156311 · Phase 2 · registry result, not featured evidence · combination
flushing 42.1%
diarrhoea 31.6%
abdominal pain 21.1%
NCT01156311 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 10 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Dimethyl fumarate (Tecfidera)

Annualized Relapse 0.224 vs 0.401 placebo per year @ 104wk240 mg twice daily
event rate · per year
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 5 more results
0.198 vs 0.401 placebo per year @ 104wk240 mg 3 times daily
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0.172 vs 0.364 placebo per year @ 104wk240 mg BID
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0.189 vs 0.364 placebo per year @ 104wk240 mg TID
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0.324 vs 0.564 Interferon β-1a per year @ 48wk
NCT02283853 · Phase 3 · registry result, not featured evidence
0.24 vs 0.528 Interferon β-1a per year @ 96wk
NCT02283853 · Phase 3 · registry result, not featured evidence
New or Newly Enlarging T2 Lesion 5.1 vs 17.4 placebo count @ 104wk240 mg twice daily
event count · count
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 5 more results
4.7 vs 17.4 placebo count @ 104wk240 mg 3 times daily
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
2.6 vs 17 placebo count @ 104wk240 mg BID
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
4.4 vs 17 placebo count @ 104wk240 mg TID
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
10 vs 11.9 Interferon β-1a count @ 24wk
NCT02283853 · Phase 3 · registry result, not featured evidence
19.4 vs 32.1 Interferon β-1a count @ 96wk
NCT02283853 · Phase 3 · registry result, not featured evidence
New T1 Hypointense Lesion 3 vs 7 placebo count @ 104wk240 mg twice daily
event count · count
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 1 more result
2.4 vs 7 placebo count @ 104wk240 mg 3 times daily
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
Relapsed Subjects 0.291% (n=359) vs 0.41% (n=363) placebo @ 104wk240 mg twice daily
event count · % of participants
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 1 more result
0.241% (n=345) vs 0.41% (n=363) placebo @ 104wk240 mg 3 times daily
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
Disability Progression 0.128% (n=359) vs 0.169% (n=363) placebo @ 104wk240 mg twice daily
event count · % of participants
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 3 more results
0.13% (n=345) vs 0.169% (n=363) placebo @ 104wk240 mg 3 times daily
NCT00451451 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0.164% (n=409) vs 0.271% (n=408) placebo @ 104wk240 mg BID
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
0.177% (n=416) vs 0.271% (n=408) placebo @ 104wk240 mg TID
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
Relapse Proportion 0.27% (n=410) vs 0.461% (n=408) placebo @ 104wk240 mg BID
responder rate · % of participants
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
show 1 more result
0.26% (n=416) vs 0.461% (n=408) placebo @ 104wk240 mg TID
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3
MRI Gadolinium Lesion-Free 93.4% (n=152) vs 62.4% (n=165) placebo @ 104wk240 mg BID
event count · % of participants
0 lesions
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 · converted to % from 142 Number of subjects as posted
show 1 more result
85.5% (n=152) vs 62.4% (n=165) placebo @ 104wk*240 mg TID
0 lesions
NCT00420212 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 · converted to % from 130 Number of subjects as posted
Relapse Occurrence 40% (n=501) @ 384wk240 mg twice daily
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT00835770 · Phase 3 · monotherapy
show 5 more results
41% (n=502) @ 384wk240 mg three times daily
NCT00835770 · Phase 3 · monotherapy
34% (n=249) @ 384wk240 mg twice daily
NCT00835770 · Phase 3 · monotherapy
36% (n=248) @ 384wk240 mg three times daily
NCT00835770 · Phase 3 · monotherapy
31% (n=118) @ 384wk240 mg twice daily
NCT00835770 · Phase 3 · monotherapy
31% (n=118) @ 384wk240 mg three times daily
NCT00835770 · Phase 3 · monotherapy
Annualized Relapse 0.159 per year @ 384wk240 mg twice daily
event rate · per year
Extension (open-label)
No placebo or comparator arm
NCT00835770 · Phase 3 · monotherapy
show 5 more results
0.179 per year @ 384wk240 mg three times daily
NCT00835770 · Phase 3 · monotherapy
0.2 per year @ 384wk240 mg twice daily
NCT00835770 · Phase 3 · monotherapy
0.199 per year @ 384wk240 mg three times daily
NCT00835770 · Phase 3 · monotherapy
0.184 per year @ 384wk240 mg twice daily
NCT00835770 · Phase 3 · monotherapy
0.212 per year @ 384wk240 mg three times daily
NCT00835770 · Phase 3 · monotherapy
EDSS 0.28 score @ 384wk240 mg twice daily
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT00835770 · Phase 3 · monotherapy
show 5 more results
0.26 score @ 384wk240 mg three times daily
NCT00835770 · Phase 3 · monotherapy
0.37 score @ 384wk240 mg twice daily
NCT00835770 · Phase 3 · monotherapy
0.53 score @ 384wk240 mg three times daily
NCT00835770 · Phase 3 · monotherapy
0.39 score @ 384wk240 mg twice daily
NCT00835770 · Phase 3 · monotherapy
0.49 score @ 384wk240 mg three times daily
NCT00835770 · Phase 3 · monotherapy
SF-36 Physical Functioning 0.73 score @ 384wk240 mg twice daily
absolute change · score
Extension (open-label)
No placebo or comparator arm
Change at Week 384: Physical Functioning Score
NCT00835770 · Phase 3 · monotherapy
show 5 more results
-4.79 score @ 384wk240 mg three times daily
Change at Week 384: Physical Functioning Score
NCT00835770 · Phase 3 · monotherapy
-7.37 score @ 384wk240 mg twice daily
Change at Week 384: Physical Functioning Score
NCT00835770 · Phase 3 · monotherapy
-6.89 score @ 384wk240 mg three times daily
Change at Week 384: Physical Functioning Score
NCT00835770 · Phase 3 · monotherapy
-6.19 score @ 384wk240 mg twice daily
Change at Week 384: Physical Functioning Score
NCT00835770 · Phase 3 · monotherapy
-6.25 score @ 384wk240 mg three times daily
Change at Week 384: Physical Functioning Score
NCT00835770 · Phase 3 · monotherapy
SF-36 - Role Physical 3.2 score @ 384wk240 mg twice daily
absolute change · score
Extension (open-label)
No placebo or comparator arm
Change at Week 384: Role-Physical Score
NCT00835770 · Phase 3 · monotherapy
show 5 more results
-2.75 score @ 384wk240 mg three times daily
Change at Week 384: Role-Physical Score
NCT00835770 · Phase 3 · monotherapy
-10 score @ 384wk240 mg twice daily
Change at Week 384: Role-Physical Score
NCT00835770 · Phase 3 · monotherapy
-8.24 score @ 384wk240 mg three times daily
Change at Week 384: Role-Physical Score
NCT00835770 · Phase 3 · monotherapy
-12.21 score @ 384wk240 mg twice daily
Change at Week 384: Role-Physical Score
NCT00835770 · Phase 3 · monotherapy
-1.04 score @ 384wk240 mg three times daily
Change at Week 384: Role-Physical Score
NCT00835770 · Phase 3 · monotherapy

+ 19 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bafiertam's landscape · Dimethyl fumarate (Tecfidera)'s landscape